"Chinook's lead candidates are focused on rare, severe kidney disorders with defined and rapid clinical pathways. These programs may also have utility in more common kidney diseases, expanding the potential patient populations. The company is backed by leading global healthcare investors, Versant Ventures, Apple Tree Partners, and Samsara BioCapital, and is based in Vancouver, BC and Seattle, WA."
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze